Date: March 24, 2014
Source: Centre for Addiction and Mental Health
Summary: A nasal spray that delivers a peptide to treat depression holds
promise as a potential alternative therapeutic approach, research shows. This
peptide treatment interferes with the binding of two dopamine receptors -- the
D1 and D2 receptor complex. The research team had found that this binding was
higher in the brains of people with major depression. Disrupting the binding
led to the anti-depressant effects.
A nasal spray that delivers a peptide to treat depression holds promise as a
potential alternative therapeutic approach, research from the Centre for
Addiction and Mental Health (CAMH) shows.
The study, led by CAMH's Dr. Fang Liu, is published online in
Neuropsychopharmacology.
In a previous study published in Nature Medicine in 2010, Dr. Liu developed a
protein peptide that provided a highly targeted approach to treating depression
that she hopes will have minimal side effects. The peptide was just as
effective in relieving symptoms when compared to a conventional antidepressant
in animal testing. However, the peptide had to be injected into the brain.
Taken orally, it would not cross the blood-brain barrier in sufficient
concentrations.
"Clinically, we needed to find a non-invasive, convenient method to deliver
this peptide treatment," says Dr. Liu, Senior Scientist in the Campbell Family
Mental Health Research Institute at CAMH. With the support of a Proof of
Principle grant from the Canadian Institutes of Health Research (CIHR), Dr.
Liu's team was able to further explore novel delivery methods.
The nasal delivery system, developed by U.S. company Impel NeuroPharma, was
shown to deliver the peptide to the right part of the brain. It also relieved
depression-like symptoms in animals.
"This study marks the first time a peptide treatment has been delivered through
nasal passageways to treat depression," says Dr. Liu, Professor in the
University of Toronto's Department of Psychiatry.
The peptide treatment interferes with the binding of two dopamine receptors --
the D1 and D2 receptor complex. Dr. Liu's team had found that this binding was
higher in the brains of people with major depression. Disrupting the binding
led to the anti-depressant effects.
The peptide is an entirely new approach to treating depression, which has
previously relied on medications that primarily block serotonin or
norepinephrine transporters.
Depression, the most common form of mental illness, is one of the leading
causes of disability globally. More than 50 per cent of people living with
depression do not respond to first-line medication treatment.
"This research brings us one step closer to clinical trials," says Dr. Liu. In
ongoing lab research, her team is experimenting to determine if they can make
the peptide break down more slowly, and travel more quickly in the brain, to
improve its anti-depressant effects.
Story Source:
The above story is based on materials provided by Centre for Addiction and
Mental Health . Note: Materials may be edited for content and
length.http://www.camh.ca/en/research/technology_transfer/technologies_for_licensing/Documents/Novel%20therapeutics%20for%20the%20treatment%20of%20depression.pdf
Journal Reference:
Virginia Brown, Fang Liu. Intranasal Delivery of a Peptide with
Antidepressant-like Effect. Neuropsychopharmacology, 2014; DOI:
10.1038/npp.2014.61
http://www.nature.com/npp/journal/vaop/naam/pdf/npp201461a.pdf
http://www.sciencedaily.com/releases/2014/03/140324090418.htm
--
--
You received this message because you are subscribed to the Google
Groups "Mental Health Advocacy (News 'N Views) India" group.
To post to this group, send email to [email protected]
To unsubscribe from this group, send email to
[email protected]
For more options, visit this group at
http://groups.google.com/group/MhaNewsViewsIndia?hl=en
-------------
Affiliated Groups : MENTAL HEALTH ADVOCACY INDIA
[email protected]
Discussions on mental health law / policy / plan monitoring / human rights etc
[email protected]
India-specific news and views related to mental health
[email protected]
Information and support to carers of people with mental health issues
[email protected]
Mutual support and sharing of experiential knowledge, skills and social
learning amongst peers
---
You received this message because you are subscribed to the Google Groups
"Mental Health Advocacy (News 'N Views) India" group.
To unsubscribe from this group and stop receiving emails from it, send an email
to [email protected].
For more options, visit https://groups.google.com/d/optout.
